DRUG/DEVICE

Treprostinil inhalation solution

ROUTE OF ADMINISTRATION

Inhaled

THERAPEUTIC PLATFORM

Tyvaso®

CLINICAL TRIAL

TERRITORY

Worldwide

COMMERCIAL PRODUCT

www.tyvaso.com

STATUS

Phase 3

(The Phase 3 INCREASE study was successful;
sNDA approved March 31, 2021)

Tyvaso® for PH WHO Group 3 is investigational and not FDA approved.